Express Pharma

Redx will become a key upcoming player in IPF treatment with FDA’s ODD for zelasudil: GlobalData

KOLs interviewed by GlobalData noted that there is a huge unmet need in the IPF space, which is pushing companies to look for incentives such as gaining ODDs and other designations from regulators to support the long-term development of these agents